Stelis Biopharma Begins Construction of Multiproduct Biologics Facility at Bioxcell Biotechnology Park, Malaysia
![](/46/pdcnewsitem/03/39/56/9OVmscAPsZir3DC.jpg)
Stelis Biopharma has announced the groundbreaking for construction of its customized, multiproduct, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia’s premier park and ecosystem for industrial and healthcare biotechnology.
Stelis Biopharma (a wholly-owned subsidiary of Strides Arcolab) and Bio-XCell had previously announced the signing of a Build and Lease agreement with Bio-XCell for the construction of the building and part of the equipment of Stelis Biopharma’s 140,000 sq. foot biologics facility, for a total project investment amount of RM201 million (USD 60 million).
“Stelis is pleased to commence work on its flagship biopharmaceutical facility in Malaysia. With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets” said Joe Thomas, CEO of Stelis Biopharma, on the occasion.
The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017 at Bio-XCell Park. The 140,000 sq ft facility will incorporate “next-gen” single-use bio-processing technology with both mammalian and microbial manufacturing suites. When complete, it will be one of the few regulated market approvable facilities in the region with end-to-end capability including sterile fill-finish across all formats. The facility will also house an R&D unit to conduct scale-up and process development studies.
“The partnership with Stelis Biopharma to build a multiproduct biologics facility from the start, is seen as a first in Bio-XCell biotechnology Park and timely given the close working relationship over the years. We are happy to see the second biopharma project to commence in Bio-XCell Park and for the facility to ground break over an aggressive construction timeline to see its operations in 2017.It is yet another positive step forward for the park to strengthen the value proposition of the Bio-XCell ecosystem as a regional hub for industrial biomanufacturing and bioprocessing” said Rizatuddin Ramli, CEO of BioXCell Malaysia.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance